Curtana Pharmaceuticals’ CT-179 is a novel, orally bioavailable small-molecule targeting OLIG2, a transcription factor driving brain tumor stem cells in glioblastoma and SHH-medulloblastoma. The FDA has cleared the Investigational New Drug application and granted Fast Track, Orphan Disease, and Rare Pediatric Disease designations, underscoring the high unmet need. Phase 1 trials are planned to assess safety and efficacy in adult glioblastoma and pediatric medulloblastoma, advancing a promising brain-penetrant therapeutic in neuro-oncology.